Trial reportThe American journal of drug and alcohol abuse2015
Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findings.
Trial report in The American journal of drug and alcohol abuse, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Herpes simplex encephalitis in a patient abusing morphine: a case report from Nepal.Annals of medicine and surgery (2012) · 2023Article
- Integrated care model and point of care diagnostics facilitate Hepatitis C treatment among patients receiving opioid agonist therapy: a retrospective review of medical records.Substance abuse treatment, prevention, and policy · 2022Article
- Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.Drug and alcohol dependence · 2021Article
- Identification and Management of Opioid Use Disorder in Primary Care: an Update.Current psychiatry reports · 2020Review
- Defining and Predicting Opioid and Cocaine Treatment Response.Substance use & misuse · 2019Article
- Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.The American journal of drug and alcohol abuse · 2018Article
- Retention in buprenorphine treatment is associated with improved HCV care outcomes.Journal of substance abuse treatment · 2017Article
- Long-term retention in Office Based Opioid Treatment with buprenorphine.Journal of substance abuse treatment · 2017Article
- Opioids and Viral Infections: A Double-Edged Sword.Frontiers in microbiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe prevalence of hepatitis-C-virus (HCV) infections is high among opioid-dependent individuals. Prior research on the simultaneous treatment of both conditions has primarily assessed success as it pertains to HCV. However, it has been noted that favorable substance use therapy outcomes may improve the likelihood of HCV-treatment initiation and success. Therefore, current guidelines for the treatment of HCV among illicit drug users suggest that treatment for addiction be given the highest priority.
objectivesTo determine whether opioid-dependent participants in a clinical trial of buprenorphine-treatment tapering regimens, who tested positive for the HCV antibody, experienced significantly different levels of opioid abstinence than those not infected.
methodsData came from the National Drug Abuse Treatment Clinical Trial Network study 0003. 516 eligible opioid-dependent participants were randomized to either a 7-day or 28-day buprenorphine tapering schedule following a 4-week buprenorphine stabilization period. Generalized estimating equations were used to test the research question.
resultsParticipants with the HCV antibody were significantly less likely to submit opioid-negative urine analyses during and/or immediately following active treatment [OR = 0.69; CI = 0.51-0.93], indicating a higher rate of opioid use among this group.
conclusionIndividualized opioid-dependence treatment strategies may be required for opioid-dependent individuals who test positive for the HCV antibody in order to ensure resources for both opioid-dependence and HCV therapies are used efficiently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.